JP2017503842A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017503842A5 JP2017503842A5 JP2016548172A JP2016548172A JP2017503842A5 JP 2017503842 A5 JP2017503842 A5 JP 2017503842A5 JP 2016548172 A JP2016548172 A JP 2016548172A JP 2016548172 A JP2016548172 A JP 2016548172A JP 2017503842 A5 JP2017503842 A5 JP 2017503842A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- cell lymphoma
- therapeutic agent
- hodgkin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461931075P | 2014-01-24 | 2014-01-24 | |
| US201461931078P | 2014-01-24 | 2014-01-24 | |
| US61/931,078 | 2014-01-24 | ||
| US61/931,075 | 2014-01-24 | ||
| US201462077127P | 2014-11-07 | 2014-11-07 | |
| US62/077,127 | 2014-11-07 | ||
| PCT/US2015/012733 WO2015112888A1 (en) | 2014-01-24 | 2015-01-23 | Apilimod compositions and methods for using same |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020201440A Division JP2021046430A (ja) | 2014-01-24 | 2020-12-04 | 癌治療のためのアピリモド（ａｐｉｌｉｍｏｄ）組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017503842A JP2017503842A (ja) | 2017-02-02 |
| JP2017503842A5 true JP2017503842A5 (https=) | 2018-03-08 |
| JP6855243B2 JP6855243B2 (ja) | 2021-04-07 |
Family
ID=53681989
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016548172A Expired - Fee Related JP6855243B2 (ja) | 2014-01-24 | 2015-01-23 | 癌治療のためのアピリモド（ａｐｉｌｉｍｏｄ）組成物 |
| JP2020201440A Pending JP2021046430A (ja) | 2014-01-24 | 2020-12-04 | 癌治療のためのアピリモド（ａｐｉｌｉｍｏｄ）組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020201440A Pending JP2021046430A (ja) | 2014-01-24 | 2020-12-04 | 癌治療のためのアピリモド（ａｐｉｌｉｍｏｄ）組成物 |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US10179135B2 (https=) |
| EP (1) | EP3096757B1 (https=) |
| JP (2) | JP6855243B2 (https=) |
| KR (1) | KR102320190B1 (https=) |
| CN (1) | CN106659716B (https=) |
| AU (1) | AU2015209133B2 (https=) |
| BR (1) | BR112016017112A2 (https=) |
| CA (1) | CA2937655C (https=) |
| IL (1) | IL246879B (https=) |
| MX (1) | MX373818B (https=) |
| RU (2) | RU2016134406A (https=) |
| WO (1) | WO2015112888A1 (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106659716B (zh) | 2014-01-24 | 2021-03-12 | 人工智能治疗公司 | 阿吡莫德组合物及其使用方法 |
| CA2966334A1 (en) * | 2014-11-07 | 2016-05-12 | Lam Therapeutics, Inc. | Apilimod for use in the treatment of colorectal cancer |
| US10206910B2 (en) * | 2014-11-07 | 2019-02-19 | Lam Therapeutics, Inc. | Apilimod for use in the treatment of renal cancer |
| US10729694B2 (en) | 2015-01-23 | 2020-08-04 | AI Therapeutics, Inc. | Anti-viral compositions containing PIKfyve inhibitors and use thereof |
| WO2016160102A1 (en) * | 2015-03-31 | 2016-10-06 | Lam Therapeutics, Inc. | Active metabolites of apilimod and uses thereof |
| TWI746449B (zh) | 2015-07-20 | 2021-11-21 | 美商Ａｉ治療公司 | 使用阿吡莫德治療癌症之方法 |
| US20190015421A1 (en) * | 2016-01-21 | 2019-01-17 | Lam Therapeutics, Inc. | Biomarkers for Treating Cancer with Apilimod |
| KR20180015441A (ko) | 2016-08-03 | 2018-02-13 | 엘지전자 주식회사 | 롤리 키보드 |
| JP2019528305A (ja) * | 2016-08-25 | 2019-10-10 | エイアイ・セラピューティクス・インコーポレーテッド | ＰＩＫｆｙｖｅ阻害薬を含む組成物およびＲＡＮＫシグナル伝達の阻害に関連する方法 |
| AU2019223014B2 (en) | 2018-02-21 | 2024-10-17 | Orphai Therapeutics Inc. | Combination therapy with apilimod and glutamatergic agents |
| US12589097B2 (en) | 2018-02-21 | 2026-03-31 | OrphAl Therapeutics Inc. | Apilimod compositions and methods of use |
| CN108743947B (zh) * | 2018-07-04 | 2020-12-15 | 复旦大学附属肿瘤医院 | 一种治疗b细胞淋巴瘤的药物组合物 |
| CN110496128B (zh) * | 2019-09-23 | 2022-09-30 | 吉林大学 | 利培酮或帕潘立酮在制备治疗弥漫性大b细胞淋巴瘤的药物中的应用 |
| KR20220140515A (ko) | 2020-01-13 | 2022-10-18 | 버지 애널리틱스, 인크. | 치환된 피라졸로-피리미딘 및 그의 용도 |
| EP4351585A1 (en) * | 2021-06-11 | 2024-04-17 | Orphai Therapeutics Inc. | Stabilized apilimod compositions and uses thereof |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5210015A (en) | 1990-08-06 | 1993-05-11 | Hoffman-La Roche Inc. | Homogeneous assay system using the nuclease activity of a nucleic acid polymerase |
| JP4071277B2 (ja) | 1993-11-12 | 2008-04-02 | ピーエイチアールアイ・プロパティーズ・インコーポレーテッド | 核酸検出用ハイブリダイゼーションプローブ、共通ステム、方法およびキット |
| US6693097B2 (en) | 2001-11-30 | 2004-02-17 | Synta Pharmaceuticals Corp. | Pyrimidine compounds |
| EA009873B1 (ru) | 2004-02-06 | 2008-04-28 | Элан Фармасьютикалз, Инк. | Способ ингибирования роста опухоли и/или метастатического прогрессирования |
| JP4926943B2 (ja) * | 2004-04-13 | 2012-05-09 | シンタ ファーマシューティカルズ コーポレーション | Ｉｌ−１２産生を阻害する二塩 |
| EP1791544A4 (en) * | 2004-09-08 | 2007-09-12 | Chelsea Therapeutics Inc | CHINAZOLINE DERIVATIVES AS METABOLIC INERT ANTIFOLATE |
| US7923557B2 (en) | 2004-11-10 | 2011-04-12 | Synta Pharmaceuticals Corporation | Process for preparing trisubstituted pyrimidine compounds |
| US7863270B2 (en) | 2005-05-13 | 2011-01-04 | Synta Pharmaceuticals Corp. | IL-12 modulatory compounds |
| WO2006128129A2 (en) * | 2005-05-26 | 2006-11-30 | Synta Pharmaceuticals Corp. | Method for treating cancer |
| EP2385053B1 (en) | 2005-11-17 | 2013-10-02 | OSI Pharmaceuticals, Inc. | Intermediates for the preparation of fused bicyclic mTOR inhibitors |
| AR057960A1 (es) | 2005-12-02 | 2007-12-26 | Osi Pharm Inc | Inhibidores de proteina quinasa biciclicos |
| US7659274B2 (en) | 2006-01-25 | 2010-02-09 | Osi Pharmaceuticals, Inc. | Unsaturated mTOR inhibitors |
| PT2038252T (pt) | 2006-07-12 | 2016-12-16 | Univ Tennessee Res Found | Acilanilidos substituidos e métodos de utilização dos mesmos |
| WO2008098058A1 (en) | 2007-02-06 | 2008-08-14 | Novartis Ag | Pi 3-kinase inhibitors and methods of their use |
| RU2438664C2 (ru) | 2007-05-15 | 2012-01-10 | Пирамал Лайф Сайнсиз Лимитед | Синергическая фармацевтическая комбинация для лечения рака |
| DE102007036076A1 (de) | 2007-08-01 | 2009-02-05 | Bayer Healthcare Aktiengesellschaft | Dipeptoid-Produgs und ihre Verwendung |
| US8193182B2 (en) | 2008-01-04 | 2012-06-05 | Intellikine, Inc. | Substituted isoquinolin-1(2H)-ones, and methods of use thereof |
| JP5258331B2 (ja) * | 2008-03-03 | 2013-08-07 | ロート製薬株式会社 | 光安定性が改善されたニューキノロン系抗菌剤含有医薬組成物 |
| US20110224223A1 (en) | 2008-07-08 | 2011-09-15 | The Regents Of The University Of California, A California Corporation | MTOR Modulators and Uses Thereof |
| EP2318406B1 (en) | 2008-07-17 | 2016-01-27 | Critical Outcome Technologies, Inc. | Thiosemicarbazone inhibitor compounds and cancer treatment methods |
| WO2011112635A1 (en) * | 2010-03-08 | 2011-09-15 | Sloan-Kettering Institute For Cancer Research | Cdc7 kinase inhibitors and uses thereof |
| CN102905707A (zh) | 2010-03-29 | 2013-01-30 | 味之素株式会社 | 含有苯基丙氨酸衍生物的医药制剂 |
| US8402515B2 (en) | 2010-05-06 | 2013-03-19 | Jonathan Weizman | Apparatus and method for establishing a peer-to-peer communication session with a client device |
| WO2011146727A1 (en) * | 2010-05-19 | 2011-11-24 | Philip Bosch | Methods of treating interstitial cystitis |
| US8709419B2 (en) | 2010-08-17 | 2014-04-29 | Hoffmann-La Roche, Inc. | Combination therapy |
| AU2011330742B2 (en) | 2010-11-19 | 2016-10-13 | Ecole Polytechnique Federale De Lausanne (Epfl) | 2-piperazin-1-yl-4H-1,3-benzothiazin-4-one derivatives and their use for the treatment of mammalian infections |
| WO2013152342A1 (en) | 2012-04-06 | 2013-10-10 | OSI Pharmaceuticals, LLC | Anti-cancer mtor inhibitor and anti-androgen combination |
| US8940742B2 (en) * | 2012-04-10 | 2015-01-27 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| CN113967253A (zh) | 2012-05-15 | 2022-01-25 | 百时美施贵宝公司 | 通过破坏pd-1/pd-l1信号传输的免疫治疗 |
| EP2903644A4 (en) | 2012-10-05 | 2016-03-09 | Cerulean Pharma Inc | TREATMENT OF CANCER |
| US9295731B2 (en) | 2013-04-01 | 2016-03-29 | Mark Quang Nguyen | Cleavable drug conjugates, compositions thereof and methods of use |
| CN106659716B (zh) | 2014-01-24 | 2021-03-12 | 人工智能治疗公司 | 阿吡莫德组合物及其使用方法 |
| US10206910B2 (en) | 2014-11-07 | 2019-02-19 | Lam Therapeutics, Inc. | Apilimod for use in the treatment of renal cancer |
| CA2966334A1 (en) | 2014-11-07 | 2016-05-12 | Lam Therapeutics, Inc. | Apilimod for use in the treatment of colorectal cancer |
| US20180015098A1 (en) | 2015-02-03 | 2018-01-18 | Lam Therapeutics, Inc. | Apilimod compositions and methods for using same |
| WO2016160102A1 (en) | 2015-03-31 | 2016-10-06 | Lam Therapeutics, Inc. | Active metabolites of apilimod and uses thereof |
| TWI746449B (zh) | 2015-07-20 | 2021-11-21 | 美商Ａｉ治療公司 | 使用阿吡莫德治療癌症之方法 |
| EP3817736A4 (en) | 2018-07-05 | 2021-07-28 | Mayo Foundation for Medical Education and Research | PIKFYVE INHIBITORS |
| US20210077500A1 (en) | 2019-09-12 | 2021-03-18 | Al Therapeutics, Inc. | Pikfyve inhibitors for cancer therapy |
-
2015
- 2015-01-23 CN CN201580016018.3A patent/CN106659716B/zh not_active Expired - Fee Related
- 2015-01-23 KR KR1020167022474A patent/KR102320190B1/ko not_active Expired - Fee Related
- 2015-01-23 BR BR112016017112A patent/BR112016017112A2/pt not_active Application Discontinuation
- 2015-01-23 US US15/113,154 patent/US10179135B2/en active Active
- 2015-01-23 WO PCT/US2015/012733 patent/WO2015112888A1/en not_active Ceased
- 2015-01-23 EP EP15740043.3A patent/EP3096757B1/en active Active
- 2015-01-23 RU RU2016134406A patent/RU2016134406A/ru not_active Application Discontinuation
- 2015-01-23 RU RU2019107011A patent/RU2019107011A/ru unknown
- 2015-01-23 MX MX2016009590A patent/MX373818B/es active IP Right Grant
- 2015-01-23 JP JP2016548172A patent/JP6855243B2/ja not_active Expired - Fee Related
- 2015-01-23 CA CA2937655A patent/CA2937655C/en active Active
- 2015-01-23 AU AU2015209133A patent/AU2015209133B2/en not_active Ceased
-
2016
- 2016-07-21 IL IL246879A patent/IL246879B/en active IP Right Grant
-
2018
- 2018-11-16 US US16/193,045 patent/US20190183902A1/en not_active Abandoned
-
2019
- 2019-12-27 US US16/728,566 patent/US11266654B2/en not_active Expired - Fee Related
-
2020
- 2020-12-04 JP JP2020201440A patent/JP2021046430A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017503842A5 (https=) | ||
| RU2019107011A (ru) | Композиции апилимода и способы их применения | |
| MX2024012131A (es) | Composicion farmaceutica, uso de la misma y metodo para tratar el cancer | |
| EP2562177A3 (en) | Transdermally deliverable buprenorphine prodrugs and abuse-resistant compositions thereof | |
| NZ604040A (en) | The use of inhibitors of bruton’s tyrosine kinase (btk) | |
| MY199967A (en) | Combinations of lsd1 inhibitors for use in the treatment of solid tumors | |
| WO2009001359A3 (en) | Compositions and methods for inhibiting expression of pro-apoptotic genes | |
| WO2015095819A3 (en) | Cancer treatment using combinations of erk and raf inhibitors | |
| WO2015097621A3 (en) | Pharmaceutical combinations | |
| JP2020505433A5 (https=) | ||
| PL2324008T3 (pl) | 3,4-diarylopirazole jako inhibitory kinazy białkowej | |
| WO2006035434A3 (en) | Oligoribonucleotides and methods of use thereof for treatment of alopecia, acute renal failure and other diseases | |
| EA201201403A1 (ru) | Очень низкодозированные твердые пероральные лекарственные формы для гзт | |
| EP4269439A3 (en) | Reducing systemic regulatory t cell levels or activity for treatment of disease and injury of the cns | |
| SG10201901677YA (en) | Corticosteroid containing orally disintegrating tablet compositions for eosinophilic esophagitis | |
| WO2018102687A3 (en) | Combination therapy for treating cancer | |
| JP2016539156A5 (https=) | ||
| JP2016529285A5 (https=) | ||
| JP2018090566A5 (https=) | ||
| MX2017012430A (es) | Formas solvatadas de un inhibidor de tirosina quinasa de bruton. | |
| PH12018502422A1 (en) | Nanoliposomal irinotecan for use in treating small cell lung cancer | |
| JP2016515586A5 (https=) | ||
| JP2017516802A5 (https=) | ||
| WO2017042633A3 (en) | Reducing systemic regulatory t cell levels or activity for treatment of disease and injury of the cns | |
| MX2022011372A (es) | Composiciones de zinc-y-pga y metodos para tratar el cancer. |